The ICON angle as the eventual JV or Lympro buyout candidate does make a lot of sense. They have the most to lose financially if AMBS decides to sell or deal with another pharma. I wonder if ICON has the right of first refusal should someone come a calllin and want to partner or buy Lympro. I would guess that ICON wants to see how Lympro does first before making an offer. But that's my baseless speculation.